Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters











Database
Language
Publication year range
1.
Low Urin Tract Symptoms ; 12(1): 68-80, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31571403

ABSTRACT

OBJECTIVE: This analysis was conducted to investigate the cardiovascular (CV) safety outcomes from the MILAI II study. MILAI II was conducted to evaluate the long-term safety and efficacy of antimuscarinic add-on therapy to mirabegron over 52 weeks in patients with overactive bladder (OAB) symptoms. METHODS: MILAI II consisted of a 2-week screening period (patients received mirabegron 50 mg once daily) plus a 52-week treatment period (patients were randomized to receive a combination of mirabegron 50 mg/d plus solifenacin 5 mg/d, propiverine 20 mg/d, imidafenacin 0.2 mg/d, or tolterodine 4 mg/d). CV safety was assessed using treatment-emergent adverse events (TEAEs), vital signs, and 12-lead electrocardiograms (ECGs). Vital signs and ECG data were evaluated for each patient using worst post-baseline values reported. RESULTS: Of 647 patients, 570 (88.1%) were female with a mean age of 65 years. CV history at baseline and CV-related concomitant medication use throughout the study were balanced between groups. The incidences of overall and drug-related CV TEAEs were ≤8.1% and ≤6.2%, respectively, for all groups. The most common TEAEs were ECG T wave amplitude decreased, ECG QT prolonged, and ventricular extrasystoles. Overall, 36 TEAEs of interest related to the CV system that were possibly/probably related to treatment were reported with similar incidences for each group. For the worst post-baseline vital signs and ECGs, no relationships were noted in terms of either timing or treatment group. CONCLUSION: A favorable CV safety profile was observed following long-term combination treatment with mirabegron and an antimuscarinic in patients with OAB symptoms.


Subject(s)
Acetanilides/therapeutic use , Cardiovascular Diseases/epidemiology , Muscarinic Antagonists/administration & dosage , Muscarinic Antagonists/adverse effects , Thiazoles/therapeutic use , Urinary Bladder, Overactive/drug therapy , Urological Agents/therapeutic use , Aged , Aged, 80 and over , Benzilates/administration & dosage , Benzilates/adverse effects , Drug Administration Schedule , Drug Therapy, Combination , Female , Humans , Imidazoles/administration & dosage , Imidazoles/adverse effects , Japan , Male , Middle Aged , Solifenacin Succinate/administration & dosage , Solifenacin Succinate/adverse effects , Tolterodine Tartrate/administration & dosage , Tolterodine Tartrate/adverse effects , Treatment Outcome
2.
Int J Urol ; 26(3): 342-352, 2019 03.
Article in English | MEDLINE | ID: mdl-30548692

ABSTRACT

OBJECTIVES: To evaluate the long-term safety (primary objective) and efficacy (secondary objective) of antimuscarinic add-on therapy in patients receiving mirabegron. METHODS: During a 2-week screening period, patients (aged ≥20 years, mirabegron treatment for ≥6 weeks, residual overactive bladder symptoms) received mirabegron 50 mg once daily. These patients were subsequently randomized to 52 weeks' treatment with mirabegron 50 mg/day plus an antimuscarinic (solifenacin 5 mg, propiverine 20 mg, imidafenacin 0.2 mg, or tolterodine 4 mg) with the potential to double the antimuscarinic dose (except for tolterodine) at week 8. Safety assessments included treatment-emergent adverse events, vital signs, 12-lead electrocardiograms, post-void residual volume, and laboratory evaluations. Efficacy was assessed using changes from baseline in overactive bladder symptom score total score; overactive bladder questionnaire short form score; micturitions, urgency episodes, urinary incontinence episodes, and urgency urinary incontinence episodes/24 h; mean volume voided per micturition; and number of night-time micturitions. RESULTS: Overall, 80.2% of patients (88.1% women, mean age 65 years) experienced at least one treatment-emergent adverse event, with similar rates for all treatments. The adverse events most commonly reported were dry mouth, nasopharyngitis, and constipation. No marked change was observed in systolic or diastolic blood pressure for any treatment, although pulse rate increased slightly in the mirabegron and propiverine, and mirabegron and tolterodine groups. For all treatments, significant improvements were observed in all efficacy parameters, including overactive bladder symptom score total and questionnaire short form scores. CONCLUSIONS: Antimuscarinic add-on therapy is well tolerated and effective after initial treatment with mirabegron in patients with overactive bladder symptoms.


Subject(s)
Acetanilides/adverse effects , Adrenergic beta-3 Receptor Agonists/adverse effects , Muscarinic Antagonists/adverse effects , Thiazoles/adverse effects , Urinary Bladder, Overactive/drug therapy , Urinary Incontinence/drug therapy , Acetanilides/administration & dosage , Adrenergic beta-3 Receptor Agonists/administration & dosage , Adult , Aged , Aged, 80 and over , Benzilates/administration & dosage , Benzilates/adverse effects , Blood Pressure/drug effects , Constipation/chemically induced , Constipation/epidemiology , Double-Blind Method , Drug Therapy, Combination/adverse effects , Drug Therapy, Combination/methods , Female , Humans , Imidazoles/administration & dosage , Imidazoles/adverse effects , Japan , Male , Middle Aged , Muscarinic Antagonists/administration & dosage , Nasopharyngitis/chemically induced , Nasopharyngitis/epidemiology , Severity of Illness Index , Solifenacin Succinate/administration & dosage , Solifenacin Succinate/adverse effects , Thiazoles/administration & dosage , Time Factors , Tolterodine Tartrate/administration & dosage , Tolterodine Tartrate/adverse effects , Treatment Outcome , Urinary Bladder, Overactive/complications , Urinary Bladder, Overactive/diagnosis , Urinary Incontinence/diagnosis , Urinary Incontinence/etiology , Xerostomia/chemically induced , Xerostomia/epidemiology
3.
Intern Med ; 56(2): 237-238, 2017.
Article in English | MEDLINE | ID: mdl-28090062
4.
J Pathol Inform ; 7: 36, 2016.
Article in English | MEDLINE | ID: mdl-27688927

ABSTRACT

BACKGROUND: Recent developments in molecular pathology and genetic/epigenetic analysis of cancer tissue have resulted in a marked increase in objective and measurable data. In comparison, the traditional morphological analysis approach to pathology diagnosis, which can connect these molecular data and clinical diagnosis, is still mostly subjective. Even though the advent and popularization of digital pathology has provided a boost to computer-aided diagnosis, some important pathological concepts still remain largely non-quantitative and their associated data measurements depend on the pathologist's sense and experience. Such features include pleomorphism and heterogeneity. METHODS AND RESULTS: In this paper, we propose a method for the objective measurement of pleomorphism and heterogeneity, using the cell-level co-occurrence matrix. Our method is based on the widely used Gray-level co-occurrence matrix (GLCM), where relations between neighboring pixel intensity levels are captured into a co-occurrence matrix, followed by the application of analysis functions such as Haralick features. In the pathological tissue image, through image processing techniques, each nucleus can be measured and each nucleus has its own measureable features like nucleus size, roundness, contour length, intra-nucleus texture data (GLCM is one of the methods). In GLCM each nucleus in the tissue image corresponds to one pixel. In this approach the most important point is how to define the neighborhood of each nucleus. We define three types of neighborhoods of a nucleus, then create the co-occurrence matrix and apply Haralick feature functions. In each image pleomorphism and heterogeneity are then determined quantitatively. For our method, one pixel corresponds to one nucleus feature, and we therefore named our method Cell Feature Level Co-occurrence Matrix (CFLCM). We tested this method for several nucleus features. CONCLUSION: CFLCM is showed as a useful quantitative method for pleomorphism and heterogeneity on histopathological image analysis.

5.
Intern Med ; 55(7): 775-8, 2016.
Article in English | MEDLINE | ID: mdl-27041163

ABSTRACT

A 72-year-old woman with a history of type 2 diabetes mellitus was brought to the ER with metformin-associated lactic acidosis. She received continuous hemofiltration and hemodialysis, but the laboratory analyses showed no improvement. She died 11 hours after admission. Metformin is minimally bound to proteins and is readily dialyzable, but a prolonged period of dialysis is required, because metformin has a very large distribution volume and is distributed to multiple compartments. The peak blood metformin level was 432 mg/L in this case, which is one of the highest metformin concentrations ever reported, and eight hours of hemodialysis were not sufficient to reduce the serum level.


Subject(s)
Acidosis, Lactic/chemically induced , Acidosis, Lactic/therapy , Diabetes Mellitus, Type 2/drug therapy , Hemodiafiltration , Hypoglycemic Agents/adverse effects , Metformin/adverse effects , Aged , Diabetes Mellitus, Type 2/physiopathology , Fatal Outcome , Female , Fluid Therapy , Humans , Hypoglycemic Agents/administration & dosage , Metformin/administration & dosage , Vasoconstrictor Agents/administration & dosage , Vasopressins/administration & dosage
7.
BJU Int ; 116(4): 612-22, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25639296

ABSTRACT

OBJECTIVE: To examine the safety and efficacy of mirabegron as 'add-on' therapy to solifenacin in patients with overactive bladder (OAB). PATIENTS AND METHODS: This multicentre, open-label, phase IV study enrolled patients aged ≥20 years with OAB, as determined by an OAB symptom score (OABSS) total of ≥3 points and an OABSS Question 3 score of ≥2 points, who were being treated with solifenacin at a stable dose of 2.5 or 5 mg once daily for at least 4 weeks. Study duration was 18 weeks, comprising a 2-week screening period and a 16-week treatment period. Patients meeting eligibility criteria continued to receive solifenacin (2.5 or 5 mg once daily) and additional mirabegron (25 mg once daily) for 16 weeks. After 8 weeks of treatment, the mirabegron dose could be increased to 50 mg if the patient's symptom improvement was not sufficient, if he/she was agreeable to the dose increase, and the investigator judged that there were no safety concerns. Safety assessments included adverse events (AEs), laboratory tests, vital signs, 12-lead electrocardiogram, QT corrected for heart rate using Fridericia's correction (QTcF) interval and post-void residual (PVR) volume. Efficacy endpoints were changes from baseline in OABSS total score, OAB questionnaire short form (OAB-q SF) score (symptom bother and total health-related quality of life [HRQL] score), mean number of micturitions/24 h, mean number of urgency episodes/24 h, mean number of urinary incontinence (UI) episodes/24 h, mean number of urgency UI episodes/24 h, mean volume voided/micturition, and mean number of nocturia episodes/night. Patients were instructed to complete the OABSS sheets at weeks -2, 0, 8 and 16 (or at discontinuation), OAB-q SF sheets at weeks 0, 8 and 16 (or at discontinuation) and patient voiding diaries at weeks 0, 4, 8, 12 and 16 (or at discontinuation). RESULTS: Overall incidence of drug-related treatment-emergent AEs (TEAEs) was 23.3%. Almost all TEAEs were mild or moderate. The most common TEAE was constipation, with similar incidence in the groups receiving a dose increase to that observed in the groups maintained on the original dose. Changes in PVR volume, QTcF interval, pulse rate and blood pressure were not considered to be clinically significant and there were no reports of urinary retention. Significant improvement was seen for changes in efficacy endpoints from baseline to end of treatment (EOT) in all groups (patients receiving solifenacin 2.5 or 5 mg + mirabegron 25 or 50 mg). CONCLUSIONS: Add-on therapy with mirabegron 25 mg once daily for 16 weeks, with an optional dose increase to 50 mg at week 8, was well tolerated in patients with OAB treated with solifenacin 2.5 mg or 5 mg once daily. There were significant improvements from baseline to EOT in OAB symptoms with combination therapy with mirabegron and solifenacin. Add-on therapy with mirabegron and an antimuscarinic agent, such as solifenacin, may provide an attractive therapeutic option.


Subject(s)
Acetanilides/adverse effects , Acetanilides/therapeutic use , Solifenacin Succinate/therapeutic use , Thiazoles/adverse effects , Thiazoles/therapeutic use , Urinary Bladder, Overactive/drug therapy , Urological Agents/adverse effects , Urological Agents/therapeutic use , Adult , Aged , Aged, 80 and over , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Treatment Outcome , Urinary Bladder, Overactive/epidemiology
8.
Hepatogastroenterology ; 50(49): 77-9, 2003.
Article in English | MEDLINE | ID: mdl-12629995

ABSTRACT

This report concerns the successful treatment with a covered self-expandable stent of an intractable thoracoesophageal fistula after total esophagectomy for esophageal cancer. Total esophagectomy was performed on a 68-year-old man who presented with a huge esophageal cancer in the lower esophagus. Massive leakage was observed on the 5th day postoperatively. Since high fever and coughing continued, he was diagnosed as having esophagothoracic fistula and pyothorax, after which fenestration of the right chest wall was performed. Although the patient's general condition was getting better, stenosis near the anastomosis (esophagogastrostomy) and the esophagothoracic fistula were resistant to treatment with balloon dilatation and repeated endoscopic mucotomy. Further treatment, consisting of glue or fibrin sealant injection was not effective. After a covered self-expandable stent had been placed endoscopically, however, the fistel was completely cured in 2 months. This new endoscopic approach thus represents a promising option for the treatment of intractable esophagothoracic fistula.


Subject(s)
Carcinoma, Squamous Cell/surgery , Empyema, Pleural/etiology , Empyema, Pleural/surgery , Esophageal Fistula/etiology , Esophageal Fistula/surgery , Esophageal Neoplasms/surgery , Esophagectomy/adverse effects , Postoperative Complications , Prosthesis Implantation , Stents , Aged , Carcinoma, Squamous Cell/diagnostic imaging , Empyema, Pleural/diagnostic imaging , Esophageal Fistula/diagnostic imaging , Esophageal Neoplasms/diagnostic imaging , Esophagoscopy , Humans , Male , Radiography
SELECTION OF CITATIONS
SEARCH DETAIL